Bisnafide

Drug Profile

Bisnafide

Alternative Names: Bisnafide dimesylate; DMP 840; NSC D640430

Latest Information Update: 15 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics
  • Mechanism of Action DNA inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 24 Feb 2000 A study has been added to the therapeutic trials and adverse events sections
  • 11 Sep 1998 A study has been added to the adverse events and therapeutic trials sections
  • 16 Jul 1998 A study has been added to the adverse events, pharmacokinetics and therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top